Company Overview
Cidara Therapeutics, Inc. operates within the healthcare sector as a biotechnology firm dedicated to developing targeted therapies for patients suffering from cancers and other serious diseases. The company's core product portfolio features rezafungin acetate, a novel molecule classified within the echinocandin group of antifungals designed for the treatment of specific medical conditions. In terms of scale, Cidara holds a market capitalization of $6.96B while employing 38 individuals to execute its research and development strategies. Although the company reports an infinite price-to-sales ratio and zero reported revenue in the trailing twelve months, the substantial market cap relative to the small employee base suggests significant valuation placed on future potential rather than current operational scale. This disparity indicates that the market is pricing the asset based on pipeline expectations and intellectual property value rather than established commercial performance or current revenue generation capabilities.
Financial Health
The financial statements for Cidara Therapeutics, Inc. reflect a net income of $-184,800,000 over the trailing twelve months and an EBITDA of $-159,776,992. The gap between the reported revenue of N/A and the significant net loss reveals a cost structure dominated by research, development, and operational expenses that exceed any current sales income, which is typical for early-stage biotechnology entities. Free cash flow stands at $-32,148,500, indicating that the company is burning through its resources to fund its development pipeline, thereby limiting immediate financial flexibility for external expansion or acquisitions. All three reported margins—the gross margin, operating margin, and profit margin—are listed as 0.0%, which reflects the absence of positive gross profit relative to revenue or the lack of net income to generate a meaningful percentage. The company maintains a cash position of $420.02M against total debt of $1.98M, resulting in a debt-to-equity ratio of 0.47. This balance sheet configuration is highly conservative, as the vast majority of liabilities are debt-free, leaving the entity with minimal leverage risk despite the negative earnings. Furthermore, the current ratio of 4.62 indicates a strong short-term liquidity position, suggesting that the company possesses more than four times the current assets required to cover its short-term obligations. However, the return on equity is -68.7% and the return on assets is -29.4%, metrics that reveal management is currently utilizing shareholder and asset bases to generate losses rather than profits. These negative return figures highlight that the company is in a phase of capital deployment where financial efficiency is measured by the velocity of drug development rather than immediate profitability.
Valuation Assessment
The valuation metrics for Cidara Therapeutics, Inc. show a P/E ratio (TTM) of N/A and a forward P/E of -30.70. The existence of a negative forward P/E combined with a missing trailing P/E implies that the market expects earnings to remain negative or that the current earnings trajectory does not support a traditional valuation multiple based on historical performance. The price-to-book ratio is 15.37, which indicates that the market is valuing the company at a significant premium over its net asset value, a common characteristic for biotechnology firms with high intellectual property value but limited tangible assets. Alternative valuation measures such as the price-to-sales ratio of inf and the EV/EBITDA of -40.95 further suggest that traditional valuation frameworks are not applicable due to the lack of revenue and negative earnings. The stock price has fluctuated between a 52-week low of $15.22 and a 52-week high of $221.42. Without a specific current share price provided in the facts, the relative position cannot be calculated, but the range itself demonstrates extreme volatility and a wide trading band typical of speculative biotech assets. The beta of 1.53 indicates that the stock price is expected to be 53% more volatile than the broader market, meaning price movements are amplified relative to general market shifts. This high beta value underscores the elevated risk profile associated with investing in the company, as price swings will be more pronounced during periods of market stress or biotechnology sector rotation.
Growth & Income
The reported revenue growth year-over-year and earnings growth year-over-year are both N/A, reflecting the current lack of established commercial revenue streams. In the absence of positive earnings to support a dividend policy, the company does not pay dividends, as indicated by a dividend yield of N/A and a payout ratio of 0.0%. This 0.0% payout ratio is sustainable given the negative net income, as the company reinvests all available resources and cash reserves into research and development rather than distributing returns to shareholders. Consequently, the overall growth and income profile is characterized by a total reliance on capital markets for funding growth, with no current income generation for investors. The company effectively channels its free cash flow, currently negative at $-32,148,500, into its core mission of developing targeted therapies, prioritizing long-term asset creation over short-term shareholder yield.